

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten! See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic in



PRODUCT INFORMATION



AZD 2014

Item No. 17378

CAS Registry No.: 1009298-59-2

Formal Name: 3-[2,4-bis[(3S)-3-methyl-4-

morpholinyl]pyrido[2,3-d]pyrimidin-

7-yl]-N-methyl-benzamide

Synonym: Vistusertib MF: $C_{25}H_{30}N_6O_3$ FW: 462.5 Purity:

UV/Vis.: λ_{max} : 222, 277, 387 nm A crystalline solid Supplied as:

-20°C Storage:

Stability: As supplied, 2 years from the QC date provided on the Certificate of Analysis, when

stored properly

Laboratory Procedures

AZD 2014 is supplied as a crystalline solid. A stock solution may be made by dissolving the AZD 2014 in the solvent of choice. AZD 2014 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide, which should be purged with an inert gas. The solubility of AZD 2014 in these solvents is approximately 0.5, 1, and 10 mg/ml, respectively.

Description

AZD 2014 is a potent, selective, ATP-competitive mTORC1/2 dual inhibitor that inhibits phosphorylation of both mTORC1 and 2 substrate proteins in whole cells. It exhibits an IC₅₀ value of 2.81 nM against the isolated recombinant enzyme and >1,000-fold selectivity against all PI3K isoforms. AZD 2014 has broad antiproliferative effects across multiple cell lines and reduces tumor growth in in vivo models of ER⁺ breast cancer. It has efficacy against acute myeloid leukemia when combined with the pan Pim kinase inhibitor AZD 1208 (Item No. 20235) and enhances the radiosensitivity of different cancer cell types.²⁻⁴

References

- 1. Guichard, S.M., Curwen, K., Bihani, T., et al. AZD2014, an inhibitor of mTORC1 and mTORC2, is highly effective in ER⁺ breast cancer when administered using intermittent or continuous schedules. Mol. Cancer Ther. 14(11), 2508-2518 (2015).
- 2. Harada, M., Benito, J., Yamamaoto, S., et al. The novel combination of dual mTOR inhibitor AZD2014 and pan-PIM inhibitor AZD1208 inhibits growth in acute myeloid leukemia via HSF pathway suppression. Oncotarget 6(35), 37930-37947 (2015).
- 3. Kahn, J., Hayman, T.J., Jamal, M., et al. The mTORC1/mTORC2 inhibitor AZD2014 enhances the radiosensitivity of glioblastoma stem-like cells. Neuro. Oncol. 16(1), 29-37 (2014).
- Yu, C.-C., Huang, H.-b., Hung, S.-K., et al. AZD2014 radiosensitizes oral squamous cell carcinoma by inhibiting AKT/mTOR axis and inducing $G_1/G_2/M$ cell cycle rrest. PLoS One 11(3), e0151942 (2016).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

uyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website

Copyright Cayman Chemical Company, 02/02/2017

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.**CAYMANCHEM**.COM